These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Grempler R; Thomas L; Eckhardt M; Himmelsbach F; Sauer A; Sharp DE; Bakker RA; Mark M; Klein T; Eickelmann P Diabetes Obes Metab; 2012 Jan; 14(1):83-90. PubMed ID: 21985634 [TBL] [Abstract][Full Text] [Related]
25. Inhibition of SGLT2: a novel strategy for treatment of type 2 diabetes mellitus. Pfister M; Whaley JM; Zhang L; List JF Clin Pharmacol Ther; 2011 Apr; 89(4):621-5. PubMed ID: 21346749 [No Abstract] [Full Text] [Related]
26. Indole-glucosides as novel sodium glucose co-transporter 2 (SGLT2) inhibitors. Part 2. Zhang X; Urbanski M; Patel M; Cox GG; Zeck RE; Bian H; Conway BR; Beavers MP; Rybczynski PJ; Demarest KT Bioorg Med Chem Lett; 2006 Mar; 16(6):1696-701. PubMed ID: 16380256 [TBL] [Abstract][Full Text] [Related]
36. Emergence of promising therapies in diabetes mellitus. Akkati S; Sam KG; Tungha G J Clin Pharmacol; 2011 Jun; 51(6):796-804. PubMed ID: 20705952 [TBL] [Abstract][Full Text] [Related]
37. Diabetes management at the end of life #258. Jeffreys E; Rosielle DA J Palliat Med; 2012 Oct; 15(10):1152-4. PubMed ID: 22957680 [No Abstract] [Full Text] [Related]